Glatiramer acetate in multiple sclerosis: a review.

Area of Science:

• Neuroimmunology
• Neurology
• Pharmacology

Background:

• Multiple sclerosis (MS) is an inflammatory autoimmune disease where axonal damage significantly contributes to long-term disability.
• Evolving understanding of MS pathogenesis highlights the need for anti-inflammatory and neuroprotective therapeutic strategies.
• Glatiramer acetate (GA), a synthetic amino acid polymer, has demonstrated therapeutic potential in MS.

Purpose of the Study:

• To evaluate the long-term efficacy and safety of glatiramer acetate (GA) in treating relapsing-remitting multiple sclerosis (RRMS).
• To investigate the mechanisms underlying GA's therapeutic effects in MS.

Main Methods:

• Clinical studies and open-label follow-up trials assessed GA's impact on relapse rates, disability progression, and MRI findings.
• Experimental allergic encephalomyelitis (EAE) model was used to evaluate GA's efficacy.
• Mechanisms of action were investigated, including T-cell responses and neurotrophic factor production.

Main Results:

• GA was effective in preventing and suppressing EAE, the animal model for MS.
• Clinical trials showed GA reduced relapse rates and affected disability progression in RRMS patients.
• Long-term follow-up confirmed sustained efficacy in slowing disability progression, consistent with MRI data.
• GA was generally well-tolerated at a standard dose of 20 mg subcutaneously daily.

Conclusions:

• Glatiramer acetate (GA) demonstrates sustained efficacy in altering the natural history of relapsing-remitting MS.
• The therapeutic action of GA is attributed to the induction of GA-reactive T-helper 2-like regulatory suppressor cells.
• GA-reactive T cells produce neurotrophic factors, such as brain-derived neurotrophic factor (BDNF), contributing to neuroprotection and axonal support.